Drug Trial Radar · NCT04088721
Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 26, 2019
Primary completion
Jul 30, 2020
Study completion Dec 11, 2020
Sponsor
- Lead sponsor
- Advagene Biopharma Co. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Clinipace Worldwide; Taipei Medical University
- First posted
- Sep 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.
Conditions
- Allergic Rhinitis
Interventions
AD17002Biological
LTh(αK) as immunomodulator
Formulation BufferOther
Formulation buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerance of AD17002 treatments in patients with HDM allergy as measured by incidence of adverse eventsTime frame: up to 51 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Medical University
Taipei, Taiwan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.